Neurogene (NASDAQ:NGNE) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Neurogene (NASDAQ:NGNE) in a research report report published on Friday, Benzinga reports. The firm currently has a $55.00 target price on the stock.

NGNE has been the topic of a number of other research reports. SVB Leerink assumed coverage on Neurogene in a research note on Monday, April 29th. They issued an outperform rating and a $46.00 price objective on the stock. Stifel Nicolaus initiated coverage on shares of Neurogene in a research report on Friday, January 5th. They set a buy rating and a $31.00 price objective for the company. TD Cowen assumed coverage on shares of Neurogene in a research note on Thursday, January 4th. They issued an outperform rating for the company. Leerink Partnrs restated an outperform rating on shares of Neurogene in a research report on Monday, April 29th. Finally, William Blair began coverage on Neurogene in a research report on Thursday, March 21st. They issued an outperform rating and a $61.00 price target for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Neurogene currently has a consensus rating of Buy and a consensus target price of $48.25.

Neurogene Stock Up 3.5 %

NGNE stock traded up $1.24 during mid-day trading on Friday, hitting $36.63. The company had a trading volume of 44,192 shares, compared to its average volume of 93,516. The firm’s 50-day moving average price is $38.32. Neurogene has a 12-month low of $12.20 and a 12-month high of $53.00. The company has a market capitalization of $471.43 million, a P/E ratio of -2.94 and a beta of 1.36.

Institutional Investors Weigh In On Neurogene

A number of institutional investors and hedge funds have recently modified their holdings of NGNE. Privium Fund Management UK Ltd purchased a new position in shares of Neurogene during the 1st quarter valued at about $274,000. Great Point Partners LLC acquired a new stake in Neurogene during the fourth quarter worth about $19,268,000. Avidity Partners Management LP purchased a new position in Neurogene during the fourth quarter valued at approximately $9,036,000. Finally, BML Capital Management LLC purchased a new position in Neurogene during the fourth quarter valued at approximately $478,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.